Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer
- 14 December 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (24) , 6987-6998
Abstract
The PPARG gene encoding the nuclear receptor PPARγ is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the RXRA gene, which encodes the heterodimeric partner of PPARγ. Here, we show that activating alterations of PPARG or RXRA lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer. Cancer Res; 77(24); 6987–98. ©2017 AACR.Keywords
All Related Versions
This publication has 57 references indexed in Scilit:
- Genome Sequencing Identifies a Basis for Everolimus SensitivityScience, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5Nature, 2010
- A scaling normalization method for differential expression analysis of RNA-seq dataGenome Biology, 2010
- Molecular mechanism of allosteric communication in the human PPARα‐RXRα heterodimerProteins: Structure, Function, and Bioinformatics, 2009
- Effects of PPAR agonists on proliferation and differentiation in human urotheliumExperimental and Toxicologic Pathology, 2008
- Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARα/γ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of ActionToxicologic Pathology, 2006
- Ligand-independent Activation of Peroxisome Proliferator-activated Receptor-γ by Insulin and C-peptide in Kidney Proximal Tubular CellsJournal of Biological Chemistry, 2004
- Principles for modulation of the nuclear receptor superfamilyNature Reviews Drug Discovery, 2004
- Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by PioglitazoneBiochemical and Biophysical Research Communications, 2000